



## Press release

### STADA attracts Bryan Kim as Global Head of Specialties

- Experienced life sciences executive Bryan Kim will join STADA from 1st April 2021, bringing extensive experience in Specialty Pharmaceuticals
- Bryan brings more than 20 years of healthcare experience, having worked in several Specialty fields, including CNS, respiratory and biologics/biosimilars
- STADA CEO Peter Goldschmidt said: "I am delighted to welcome Bryan to STADA. His extensive experience and expertise fits perfectly with STADA's growing portfolio and pipeline of Specialty Pharmaceuticals, which complements our leading positions in Consumer Healthcare and Generics."

**Bad Vilbel, March 5, 2021** – Experienced life sciences leader Bryan Chu Young Kim will strengthen the global STADA Leadership Team as Head of Global Specialties from 1 April 2021. The former Samsung Bioepis, Boehringer Ingelheim and Pfizer executive will oversee STADA's rapidly expanding portfolio and pipeline of differentiated prescription Specialty Pharmaceuticals, reporting to STADA CEO Peter Goldschmidt.

"I am delighted to bring Bryan into our global leadership team," Goldschmidt stated.

"His extensive experience and expertise fits perfectly with STADA's growing portfolio and pipeline of Specialty Pharmaceuticals, which complements our leading positions in Consumer Healthcare and Generics."

Bryan brings more than 20 years of healthcare and pharmaceutical experience, gathered across the US, Europe and Asia. In particular, he has detailed knowledge of central nervous system therapies, an area in which STADA is building a comprehensive, differentiated Parkinson's disease portfolio with a unique triple-combination pump product complementing the group's established apomorphine-based therapies.

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Miguel Pagan Fernandez  
Supervisory Board Chairman: Dr. Günter von Au



In recent years, Bryan has focused particularly on biologic drugs, including follow-on biosimilar medicines.

He was most recently Vice-President, Corporate Development, at South Korean biosimilars developer and manufacturer Samsung Bioepis. In this role, he led a team of business-development professionals and oversaw all biosimilar licensing, alliance and other deals.

A driven and empathetic leader with proven ability to motivate cross-functional and global teams, Bryan has a track record of successful business development, having worked on more than a dozen major transactions.

During more than four years with Boehringer Ingelheim, Bryan worked on biosimilars, as well as on global launches and marketing of respiratory brands. He also led the German company's prescription medicines business as regional executive director for Greater China, South Korea, South-East Asia and India. His roles at Pfizer's headquarters in New York, US, included Director of Marketing, CNS. He also has extensive experience of US healthcare policy and advocacy, including digital health, at companies such as Booz & Co and Intel Corporation.

Bryan's areas of expertise include growth strategies, business development, alliance management, organizational transformation, brand management, multi-channel marketing, and launch excellence. He holds a Bachelor of Arts in Public Health/Pre-Medicine from Johns Hopkins University and a Master's degree in Business Administration (MBA) from Yale University.

"I look forward to joining STADA and becoming part of an agile company that is consistently outgrowing the industry," Bryan Kim commented. "STADA has already built up a considerable presence in the Specialty Pharma space with products such as

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Miguel Pagan Fernandez  
Supervisory Board Chairman: Dr. Günter von Au



Parkinson's disease treatments and specialty biologics. I look forward to accelerating the group's Specialty growth as a go-to-partner for value-added treatment options that can truly make a difference to people's health."

**About STADA Arzneimittel AG**

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.

***Additional information for journalists:***

STADA Arzneimittel AG / Media Relations  
Stadastrasse 2-18 / 61118 Bad Vilbel / Germany  
Phone: +49 (0) 6101 603-165  
Fax: +49 (0) 6101 603-215  
E-Mail: [press@stada.de](mailto:press@stada.de)  
Or visit us on the Internet at [www.stada.com/press](http://www.stada.com/press)

***Additional information for capital market participants:***

STADA Arzneimittel AG / Investor & Creditor Relations  
Stadastrasse 2-18 / 61118 Bad Vilbel / Germany  
Phone: +49 (0) 6101 603-4689  
Fax: +49 (0) 6101 603-215  
E-mail: [ir@stada.de](mailto:ir@stada.de)  
Or visit us on the Internet at [www.stada.com/investor-relations](http://www.stada.com/investor-relations)

Executive Board: Peter Goldschmidt (CEO) / Dr. Wolfgang Ollig / Miguel Pagan Fernandez  
Supervisory Board Chairman: Dr. Günter von Au